Operating cash flow ran at roughly 0.64 to 1.04 times net loss, with free cash flow of -$83.2M in 2027Q2 and negligible capital expenditure, indicating an asset-light model whose cash burn is largely real rather than driven by non-cash charges.
Immunovant, Inc. (IMVT) cash flow statement — 9-year operating, investing & financing cash flows
| Metric | TTM | Mar'26 | Mar'25 | Mar'24 | Mar'23 | Mar'22 | Mar'21 | Mar'20 | Mar'19 | Mar'18 |
|---|
| Cash from Operations | -395M | -407.31M | -375.87M | -214.23M | -188.19M | -106.11M | -83.33M | -53.36M | -28.55M | -128.3M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | 34.98% | -8.36% | -75.46% | -13.83% | -77.35% | -27.34% | -56.17% | -86.91% | 77.75% | - |
| Net Income | -508.96M | -505.61M | -413.84M | -259.34M | -210.96M | -156.73M | -107.43M | -66.39M | -28.6M | -136.74M |
| Depreciation & Amortization | 378K | 409K | 377K | 231K | 193K | 126K | 65K | 21K | 10K | 136.74M |
| Stock-Based Compensation | 50.91M | 55.72M | 49.49M | 41.12M | 32.3M | 34.24M | 0 | 6.96M | 1.31M | 1.81M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 105K | 99K | 133K | 1.13M | 1.13M | 1.11M | 19.47M | 1.24M | -792K | -131.55M |
| Working Capital Changes | 62.56M | 42.06M | -12.03M | 2.63M | -10.85M | 15.14M | 4.57M | 4.81M | -474K | 1.44M |
| Change in Receivables | -510K | -1.4M | 2.97M | -4.56M | 12.22M | -11.72M | 2.5M | -83K | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -540K | -10.25M | 10.68M | 5.78M | -17.12M | 16.25M | 1.25M | 967K | 0 | 0 |
| Cash from Investing | -8K | -8K | -759K | -360K | -197K | -254K | -210K | -31K | -52K | 0 |
| Capital Expenditures | -8K | -8K | -759K | -360K | -197K | -254K | -210K | -31K | -52K | 0 |
| CapEx % of Revenue | 0.11% | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 596.22M | 595.76M | 454.49M | 472.43M | 70.89M | 200.13M | 383.11M | 146.97M | 35.58M | 128.3M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | -3.19M | 37.91M | 0 | 0 |
| Equity Issued (Net) | 596.14M | 596.26M | 450M | 472.75M | 70.5M | 129K | 386.3M | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 82K | -504K | 4.49M | -318K | 385K | 200M | 0 | 109.07M | 35.58M | 128.3M |
| Net Change in Cash | 200.4M | 188.14M | 78.61M | 258.83M | -117.28M | 93.67M | 299.57M | 93.59M | 6.99M | 0 |
| Free Cash Flow | -395.01M | -407.32M | -376.63M | -214.59M | -188.39M | -106.37M | -83.54M | -53.39M | -28.6M | -128.3M |
| FCF Margin % | -5567.47% | - | - | - | - | - | - | - | - | - |
| FCF Growth % | 8.42% | -8.15% | -75.52% | -13.91% | -77.11% | -27.33% | -56.47% | -86.68% | 77.71% | - |
| FCF per Share | -1.91 | -2.23 | -2.48 | -1.55 | -1.53 | -0.97 | -0.95 | -1.24 | -1.99 | -12.83 |
| FCF Conversion (FCF/Net Income) | 0.78x | 0.81x | 0.91x | 0.83x | 0.89x | 0.68x | 0.78x | 0.80x | 63720.98x | 0.94x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | -51K | 2.39M | 1.2M | 509K | 0 | 0 | 0 | 61K | 0 | 0 |
Quick answers to the most common questions about buying IMVT stock.
Immunovant, Inc. (IMVT) generated $-407.3M in net cash from operating activities in 2026. This reflects the cash generated directly from core business operations.
Immunovant, Inc. (IMVT) reported negative free cash flow of $407.3M in 2026, indicating capital requirements exceeded cash from operations.
Immunovant, Inc. (IMVT) spent $0.0M on capital expenditures in 2026. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
Key Metrics
Top Statement Risk
Continued cash burn dependence
Metrics are mathematically derived from official filings.
Operating Cash Burn Tracks Losses Closely
Based on reported quarterly figures, IMVT's operating cash flow ran at roughly 0.64 to 1.04 times net loss across ten quarters, meaning non-cash charges explain only a modest share of the reported losses and cash burn is largely real.
The consistency of the operating cash flow to net income ratio near 0.8 to 0.9 suggests that the loss figures reflect genuine cash outflows rather than accounting noise. Stock-based compensation of $11M to $18M per quarter is small against losses of $87M to $153M, which reinforces that equity-based charges do not materially distort the earnings picture. Investors should treat reported losses as a reasonable proxy for underlying cash consumption rather than expecting a meaningful non-cash cushion.
Free Cash Flow Deficit Persists Without Inflection
According to reported cash flow statements, IMVT's free cash flow remained negative in every quarter shown, ranging from roughly -$76M to -$124M, with no sign of narrowing toward breakeven over the period.
Quarterly free cash flow shows no sustained improvement trend, with the 2027Q1 burn of $124.4M exceeding the first-quarter 2025 burn of $76.4M by a wide margin. Because capital expenditure is effectively nil, the burn is driven almost entirely by operating outflows tied to clinical development. This pattern suggests the funding requirement is structural and tied to program spending rather than a temporary working capital effect.
Negligible Capital Intensity Reflects Outsourced Model
As reported in financial statements, IMVT recorded capital expenditure of effectively zero to roughly $0.2M per quarter, with D&A near $0.1M, indicating an asset-light structure that relies on third parties for manufacturing and trial execution.
Near-zero capex and depreciation imply the company owns little fixed infrastructure, which is typical of a clinical-stage biologics developer dependent on contract manufacturers. This lowers the capital needs of the business but concentrates cost risk in outsourced contracts whose terms are not visible in these figures. The absence of maintenance capex means the cash burn is not being masked by infrastructure reinvestment.
Working Capital Swings Add Quarterly Volatility
Based on reported figures, IMVT's working capital changes ranged from a $41.5M inflow to a $16.0M outflow across quarters, adding meaningful noise to quarterly operating cash flow without altering the underlying burn direction.
Large swings in working capital, such as the $41.5M inflow in 2026Q4 and the $15.4M and $16.0M outflows in early 2026 and late 2025, appear to reflect timing of payables and accrued clinical expenses rather than durable cash generation. Investors should avoid annualizing any single quarter's operating cash flow, as the timing of trial-related payments may materially distort reported quarterly burn. The net effect across the period still points toward sustained consumption.
Cumulative Burn Exposes Funding Dependence
Based on the ten reported quarters, IMVT accumulated roughly $1.0B of negative free cash flow, a scale that implies continued reliance on external capital given the absence of commercial revenue offsets.
Summing the quarterly free cash flow figures yields a cumulative burn near $1.0B over roughly two and a half years, which is large relative to the company's pre-revenue profile. The pattern suggests that without commercial inflows the company must rely on equity financing or existing reserves to fund ongoing development. This warrants investigation of runway disclosures and any financing activity to assess the timing and dilution implications.
Stock Compensation Does Not Explain the Burn
Based on reported figures, IMVT's stock-based compensation of roughly $11M to $18M per quarter is far smaller than the $87M to $153M quarterly net losses, suggesting the cash burn is not an artifact of non-cash equity charges.
Because SBC is a minor fraction of losses, the apparent cash deficit is unlikely to be overstated by equity-compensation add-backs that would otherwise flatter operating cash flow. The more plausible explanation is that clinical and R&D spending drives the outflows, consistent with the earlier income statement finding that development costs dominate the operating base. Investors should instead focus on dilution risk, since a funding model reliant on equity may transfer the economic cost of the burn to shareholders through future issuances.